OABI · OmniAb, Inc. · Metrics
$4.87
-0.12 (-2.40%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$670.25M
Shares
145.39M
Volume · Oct 2
1.62M
Avg daily vol (3M)
1.42M
OABI metrics
62 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$4.87
Market cap
$670.25M
Price action
20 metricsPrice change (1W)
+5.6%
Price change (30D)
+12.5%
Price change (3M)
+101.2%
Price change (6M)
+216.2%
Price change (YTD)
+163.2%
Price change (1Y)
+202.5%
Trailing year
Price change (5Y)
-51.3%
52-week high
$5.04
52-week low
$1.36
Change from 52-week high
-3.4%
Change from 52-week low
+258.1%
Annualized volatility
75.8%
Annualized volatility (3M)
101.8%
Beta
1.4
RSI (14D)
61.4
Price vs SMA 50
+25.9%
Price vs SMA 200
+101.5%
Avg volume (3M)
1.42M
Relative volume
1.2
Average dollar volume
$5.67M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
145.39M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
17.4×
reciprocal yield 5.7%
P / book
2.6
reciprocal yield 38.8%
FCF yield
-2.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-6.6%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-06
Profitability
9 metricsGross margin
—
Operating margin
-125.8%
Trailing 12 months
Net margin
-115.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$48.37M
Net income (TTM)
−$44.27M
Trailing 12 months
Diluted EPS (TTM)
$-0.36
FCF margin
-47.2%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+244.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$38.46M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+21.3%
Year over year · more shares
Revenue CAGR (3Y)
-31.9%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-17.0%
Return on assets
-15.3%
Debt / equity
—
Current ratio
4.8
EBITDA (TTM)
−$47.22M
Free cash flow (TTM)
−$18.14M
Quick ratio
4.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$24.34M
Latest balance sheet
Cash & equivalents
$24.34M
Total assets
$290.26M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$17.67M
Capital expenditures (TTM)
$468,000
R&D (TTM)
$43.51M
SG&A (TTM)
—
Stock compensation (TTM)
$14.07M
R&D / revenue
113.1%
Stock compensation / revenue
36.6%
Ownership (13F)
3 metrics13F filers
144
13F filer change QoQ
+5
Institutional ownership
42.5%
Short interest
3 metricsShort interest
4.9%
Latest settlement · 4.1 days to cover
Days to cover
4.1d
Short-squeeze score
75 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—